News &amp; Updates

No cardiovascular signal with anti-CGRP mAbs for migraine

Migraine treatment with monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) or its receptor does not appear to contribute to increased risk of cardiovascular disease (CVD) compared with onabotulinumtoxinA in adults, including those who are older and with disability, according to a retrospective cohort study.

No cardiovascular signal with anti-CGRP mAbs for migraine

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

05 Mar 2025 by

The combination of nivolumab and ipilimumab (NIVO + IPI) significantly improves overall survival (OS) and objective response rate (ORR) compared with lenvatinib or sorafenib (LEN/SOR) in the first-line setting for patients with unresectable hepatocellular carcinoma (uHCC), based on the CheckMate 9DW expanded analyses presented at ASCO GI 2025.

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

De-escalating ticagrelor monotherapy reduces bleeding in ACS

De-escalation of dual antiplatelet therapy (DAPT) to ticagrelor monotherapy results in a decreased risk for major bleeding compared with standard DAPT among patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, reports a study.

De-escalating ticagrelor monotherapy reduces bleeding in ACS

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

04 Mar 2025 by

Two-year treatment with brolucizumab 6 mg every 4 weeks demonstrates noninferiority in mean best-corrected visual acuity (BCVA), with superior anatomic outcomes, to aflibercept 2 mg every 4 weeks in patients with neovascular age-related macular degeneration (nAMD), as shown in the MERLIN study.

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

Does SEP-1 increase sepsis mortality?

Implementation of or compliance with the Severe Sepsis and Septic Shock Management Bundle (SEP-1) does not appear to contribute to mortality among patients with sepsis, as shown by the results of a systematic review.

Does SEP-1 increase sepsis mortality?

Oestradiol patches bump up ADT armamentarium for prostate cancer

04 Mar 2025 by

Findings from a phase II trial demonstrate the potential of transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT) for men with metastatic (M1) prostate cancer who are on androgen receptor pathway inhibitors (ARPI).

Oestradiol patches bump up ADT armamentarium for prostate cancer

04 Mar 2025

Age does not influence ferric derisomaltose treatment outcomes

In the treatment of patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency, the use of ferric derisomaltose appears to result in similar outcomes across age groups, according to data from the open-label IRONMAN trial.

Age does not influence ferric derisomaltose treatment outcomes

Singaporean youths grapple with depression, anxiety

03 Mar 2025 by

A significant portion of Singapore’s youth are experiencing ‘severe’ to ‘extremely severe’ levels of depression and anxiety, according to the National Youth Mental Health Study.

Singaporean youths grapple with depression, anxiety

GLP-1RAs lower depression risk in older adults with T2D

The incidence of depression among older adults with type 2 diabetes is low, and the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) helps reduce the risk of depression relative to dipeptidyl peptidase-4 inhibitors (DPP4is), but not sodium–glucose cotransporter-2 inhibitors (SGLT2is).

GLP-1RAs lower depression risk in older adults with T2D